The Journal of Clinical Psychopharmacology Podcast
Episodes
Current Clinical Psychopharmacology Integrated Practice: The Crisis in Teaching and Its Effects on Quality of Care
04 Mar 2026
Contributed by Lukas
Why can it be challenging to find a psychiatrist well-trained in psychopharmacology? An editorial in the March-April 2026 issue of the Journal of Cli...
The Use of VMAT2 Inhibitors for Tardive Dyskinesia
04 Mar 2026
Contributed by Lukas
In this podcast, Orges Alabaku discusses his article, "The Use of VMAT2 Inhibitors for Tardive Dyskinesia," which is published in the March-April 202...
Reduction of Loss of Control Eating in Youth With Attention-Deficit/Hyperactivity Disorder Following Initiation of Stimulant Medication: A Prospective Study
19 Dec 2025
Contributed by Lukas
In youth, binge eating is often marked by loss of control eating (LOC-E), defined as difficulty stopping eating and persistent, compulsive food-seek...
Esketamine and Quality of Life Improvement in Treatment-Resistant Depression Patients: A Real-World Clinical Study
19 Dec 2025
Contributed by Lukas
Treatment-resistant depression (TRD) is a considerable clinical challenge. Esketamine, in conjunction with an oral antidepressant, is a potential tr...
Atomoxetine as a Viable ADHD Treatment in Breastfeeding Mothers: Evidence From Human Milk Pharmacokinetic Analysis
19 Dec 2025
Contributed by Lukas
Atomoxetine is a selective norepinephrine reuptake inhibitor prescribed for the management of attention-deficit hyperactivity disorder (ADHD). In t...
Diet Drug Interactions: Achieving and Maintaining Ketosis As Adjunct to Psychotropic Polypharmacotherapy
03 Nov 2025
Contributed by Lukas
As interest grows in the therapeutic potential of ketogenic diets for bipolar disorder, careful attention must be given to drug-diet interactions. Ove...
Anticholinergic Equivalence in Psychotropic Medications: A Guide for Psychiatrists
03 Nov 2025
Contributed by Lukas
In this podcast, Nicolas Badre, MD, and Eric Geier, MD, PhD, discuss their article, "Anticholinergic Equivalence in Psychotropic Medications: A Guide ...
Fact Versus Fear: Antidepressants in Children and Adolescents
27 Aug 2025
Contributed by Lukas
A presidential executive order early this year directed federal departments and agencies to address the issue of chronic disease in the United States,...
How Does Positive Mental Health Affect Next-Step Treatment Outcomes in Treatment-Resistant Depression?
27 Aug 2025
Contributed by Lukas
Many patients view the return of "positive mental health" (PMH) to be their most important goal of treatment for major depressive disorder (MDD). Howe...
Variability in Response to Antidepressants
27 Aug 2025
Contributed by Lukas
Antidepressants are in widespread use, but there is considerable variability in how patients respond, with some seeing substantial improvement while o...
A Systematic Review to Determine if Family History of Response to Medication Predicts Outcome in Mood Disorders
25 Jun 2025
Contributed by Lukas
Examining a patient's family history of medication response is a commonly used method to guide physicians in treatment selection. Though it is widely ...
How Does Drug Company Marketing Affect Physician Prescribing?
25 Jun 2025
Contributed by Lukas
There is considerable evidence that marketing affects physician prescribing practices, even though physicians themselves may not feel that they are i...
A Call for Updates to Clozapine's Product Label
07 May 2025
Contributed by Lukas
It has been more than 35 years since clozapine was approved by the FDA for use in the United States. Since then, there have been major advances in pha...
Practical Strategies for Prescribing Clozapine
07 May 2025
Contributed by Lukas
Dr. Jose de Leon speaks with Dr. Julia Ann Koretski, the Journal of Clinical Psychopharmacology's Digital Editor, about practical strategies for clini...
At Last, a Nondopaminergic Agent for the Treatment of Schizophrenia: The Combination of Xanomeline and Trospium (Cobenfy)
04 Mar 2025
Contributed by Lukas
Dr. Donald C. Goff, Marvin Stern professor of psychiatry at NYU Grossman School of Medicine, gives an overview of a new combination drug recently appr...
Clinical Management of Designer Benzodiazepine Intoxication: A Systematic Review
04 Mar 2025
Contributed by Lukas
"Designer benzodiazepines" are lab-created chemical derivatives of prescription benzodiazepines. They have not been approved for medical use and there...
Growing Concerns Over Valproate Teratogenicity Present an Opportunity for Lithium
04 Mar 2025
Contributed by Lukas
Valproic acid is one of the most frequently prescribed mood-stabilizing agents for bipolar disorder, and in some regions of the world, it now competes...
Ethics in Psychedelic Science: Promises and Responsibilities
06 Jan 2025
Contributed by Lukas
Dr. Julia Ann Koretski, a psychiatrist and Digital Editor of the Journal of Clinical Psychopharmacology (JCP), leads a conversation about the guest e...
Broad-Spectrum Micronutrients or Antidepressants for Antenatal Depression: Effect on Maternal and Infant Birth Outcomes in an Observational Secondary Analysis of NUTRIMUM
06 Jan 2025
Contributed by Lukas
About 20% of women experience depression while they are pregnant, and untreated depression has been associated with increased rates of adverse birth ...
Psychopharmacologic Laziness
25 Oct 2024
Contributed by Lukas
Dr. Julia Ann Koretski, a psychiatrist and Digital Editor of Journal of Clinical Psychopharmacology (JCP), discusses the editorial "Psychopharmacol...
Health Alert: Microdose Products Leading to Acute Illness and Hospitalizations Across the United States
25 Oct 2024
Contributed by Lukas
According to the US Centers for Disease Control and Prevention, products containing psychoactive compounds such as cannabis or mushroom extracts are ...
Fluoxetine and Sertraline Inhibit Height Growth and Growth Hormone Signaling During Puberty
25 Oct 2024
Contributed by Lukas
This podcast features Dr. Chadi Calarge, a child psychiatrist at Baylor College of Medicine and, for over 20 years, a researcher focused on long-term...
Ketamine and Esketamine for Depression in Daily Practice: Opportunities and Challenges
26 Aug 2024
Contributed by Lukas
Ketamine and esketamine represent significant advancements for patients with treatment-resistant depression. Their rapid action provides much needed r...
High-dose propranolol for severe and chronic aggression in autism spectrum disorder
26 Aug 2024
Contributed by Lukas
The symptoms of irritability associated with autism spectrum disorder (ASD) include aggression, tantrums, self-injury, and disruption. Propranolol, a ...
Prebiotic Treatment in People With Schizophrenia
26 Aug 2024
Contributed by Lukas
It has been hypothesized that alterations in the gut microbiota may play a part in the pathophysiology of schizophrenia, including immune system dysfu...
Challenges in the Treatment of Psychotic Bipolar Depression
19 Jun 2024
Contributed by Lukas
Psychotic bipolar depression (PBD) is a prevalent yet understudied psychiatric illness with no specific guidelines or Food and Drug Administration-ap...
Floxing and Clinical Psychopharmacology
19 Jun 2024
Contributed by Lukas
There are two distinct and unrelated definitions of the word "floxing." In this podcast, the author of an editorial in the July-August 2024 issue o...
A Case of Tachyphylaxis After Long-Term Intravenous Racemic Ketamine for Treatment-Resistant Depression
29 Apr 2024
Contributed by Lukas
Tachyphylaxis is a phenomenon described as the loss of response to a medication that was previously effective at an established dose. In a case repor...
Glucagon-Like Peptide 1 Receptor Agonists in Psychiatry
29 Apr 2024
Contributed by Lukas
The glucagon-like peptide 1 (GLP-1)–based diabetes and obesity drug semaglutide, with trade names Ozempic and Wegovy, will become the second best-se...
Clinical Presentations of Bupropion Prescription Drug Misuse: A Systematic Review
29 Apr 2024
Contributed by Lukas
Among most prescribers, bupropion is considered a substance of low misuse potential, with some studies showing lesser misuse potential than caffeine. ...
The Role of Case Series and Case Reports in Evidence-Based Medicine
28 Feb 2024
Contributed by Lukas
In a guest editorial in the Journal of Clinical Psychopharmacology, authors Eric G. Smith and Kushani M. Patel discuss how case series and case rep...
Current Status and Treatment of Rapid Cycling Bipolar Disorder
28 Feb 2024
Contributed by Lukas
"Rapid cycling" in bipolar disorder is defined by the occurrence of at least 4 episodes of mania, hypomania, depression, or mixed states during the ...
GLP-1 Weight Loss Drugs in Patients With Bipolar Disorder or Eating Disorders
28 Feb 2024
Contributed by Lukas
Two articles in the March-April 2024 issue of the Journal of Clinical Psychopharmacology present research on glucagon-like peptide-1 receptor agoni...
Celebrating 70 Years of the First Publication on Antipsychotic Treatment in North America by Heinz E. Lehmann and Gorman E. Hanrahan: Would Their Methodology Still Be Conceivable?
15 Dec 2023
Contributed by Lukas
In 1954, Dr Heinz Lehmann published the first clinical article on the use of chlorpromazine. Chlorpromazine was the first synthetic drug used to contr...
Direct-to-Consumer Advertising Survey of Psychiatrists in Massachusetts and Michigan
15 Dec 2023
Contributed by Lukas
We have all seen the television commercials imploring viewers to "ask your doctor" about Drug X, Y, or Z. The authors of a study in the Journal of Cli...
The Need for Examining the Role of Psychostimulants in Treatment of Methamphetamine Use/Dependence
01 Nov 2023
Contributed by Lukas
Replacement therapy is a key tool in the treatment of individuals who abuse opioids. The idea is to replace heroin or morphine with less euphoric and...
Assessing Adherence to Clozapine: Practical Considerations
06 Sep 2023
Contributed by Lukas
Clozapine is an important drug in the treatment of schizophrenia, and adherence is generally thought to be as good as, if not better than, other antip...
Artificial Intelligence and the Journal of Clinical Psychopharmacology
06 Sep 2023
Contributed by Lukas
Much has been written in recent months regarding the growing use of artificial intelligence (AI) in medicine and the potential benefits and risks of i...
Adherence to Psychotropic Medication Before and During COVID-19: A Population-Wide Retrospective Observational Study
30 Jun 2023
Contributed by Lukas
The COVID-19 pandemic and associated public health measures shifted the way people access health care. In this podcast, Dr. Christine Leong, Associat...
A System for Rapidly Yet Rigorously Evaluating the Quality of Randomized Controlled Trials
30 Jun 2023
Contributed by Lukas
The July-August 2023 issue of the Journal of Clinical Psychopharmacology features a helpful tutorial written by Drs. Eric G. Smith and Hannah L. Grig...
Valproic Acid–Associated Hyperammonemia: A Systematic Review
25 Apr 2023
Contributed by Lukas
Hyperammonemia is an adverse effect that poses clinical uncertainty regarding the prescription of valproic acid (VPA) use. The prevalence of symptoma...
Anosognosia and Psychosis: More Research is Needed on How Best to Treat People Unaware of Their Disorder
25 Apr 2023
Contributed by Lukas
Among individuals with schizophrenia, an estimated 50% to 80% have a partial or even total lack of insight into the presence of their mental disorder...
κ-Opioid Receptor Plasma Levels Are Associated With Sex and Diagnosis of Major Depressive Disorder But Not Response to Ketamine
24 Feb 2023
Contributed by Lukas
For individuals with treatment-resistant depression, ketamine can be an effective fast-acting alternative to conventional antidepressants. It has been...
Feasibility and Effect of Increasing Clozapine Plasma Levels in Long-Stay Patients With Treatment-Resistant Schizophrenia
24 Feb 2023
Contributed by Lukas
Clozapine is a unique antipsychotic with superior efficacy in treatment-resistant schizophrenia (TRS). Unfortunately, approximately 40% to 70% of pati...
Real-World Clinical Practice Among Patients With Bipolar Disorder and Chronic Kidney Disease on Long-term Lithium Therapy
03 Jan 2023
Contributed by Lukas
Lithium is considered a standard treatment for bipolar disorder, but it remains underprescribed, in part because of its association with kidney dysfun...
Endoxifen Approval for Bipolar Disorder in India: A Premature or a Pragmatic Decision?
03 Jan 2023
Contributed by Lukas
In a commentary published in the Journal of Clinical Psychopharmacology, Dr. Rishab Gupta (Brigham and Women's Hospital/Harvard Medical School) and Dr...
Psychedelics in the Treatment of Depression: A Critical Appraisal of Evidence
04 Nov 2022
Contributed by Lukas
Psychedelics as a potential treatment for depression is an irresistible topic in the mainstream press, but what is the evidence base for their use? In...
The Modernization of Clozapine: A Recapitulation of the Past in the United States and the View Forward
04 Nov 2022
Contributed by Lukas
In this podcast, Dr. Jonathan Leung discusses the article, "The Modernization of Clozapine: A Recapitulation of the Past in the United States and the ...
Effects of Selective Serotonin Reuptake Inhibitor Use on MDMA–Assisted Therapy for Posttraumatic Stress Disorder
30 Aug 2022
Contributed by Lukas
In small-scale studies, 3,4-methylenedioxymethamphetamine (MDMA)-assisted therapy for posttraumatic stress disorder has shown some promise, but explor...
Exposure to SARS-CoV-2, Acute Kidney Injury, and Lithium Toxicity
30 Aug 2022
Contributed by Lukas
In this podcast, Dr. Melvin McInnis discusses lithium toxicity in individuals with bipolar disorder who were infected by the SARS-CoV-2 virus. Lithium...
Panic Disorder Seeks More Specific Drugs for Treatment : Might the Amygdala Be the Best Target?
30 Aug 2022
Contributed by Lukas
Panic disorder is a common psychiatric disorder, with generally effective pharmacologic treatments for most patients. However, a subset of patients do...
Unfair Criticisms of Psychopharmacology
01 Jul 2022
Contributed by Lukas
A recently published book provides sharp criticism of the modern era of clinical psychopharmacology, questioning the validity of psychiatric diagnoses...
Clozapine Rechallenge or Continuation Despite Neutropenia, an Extended Follow-up of a Consecutive Quebec Case Series
01 Jul 2022
Contributed by Lukas
Clozapine is often prescribed for patients with treatment-resistant schizophrenia, but its use is sometimes discontinued if it is suspected of indu...
Should Antipsychotic Medications Be Prescribed to Patients with Nonpsychotic Depression?
29 Apr 2022
Contributed by Lukas
In this podcast, Editor-in-Chief Anthony Rothschild discusses his editorial in the May-June 2022 issue about the use of antipsychotic medications for ...
Acute Hyperkinetic Movement Disorders as a Multifactorial Pharmacodynamic Drug Interaction Between Methylphenidate and Risperidone in Children and Adolescents
29 Apr 2022
Contributed by Lukas
The use of the combination of stimulants and antipsychotic medications is increasing in pediatric patients who suffer from Attention Hyperactivity Dis...
Calcium Channel Antagonists for Mood Disorders
01 Mar 2022
Contributed by Lukas
Drs. Steve Dubovsky and Dori Marshall discuss their article reviewing the potential of calcium channel blockers for the treatment of mood disorders, a...
Structured Interventions to Optimize Polypharmacy in Psychiatric Treatment and Nursing Homes: A Systematic Review
01 Mar 2022
Contributed by Lukas
"Polypharmacy," the simultaneous use of multiple medications, has been linked to an increased risk of treatment complications. An article in the March...
Raising the Quality of Psychopharmacology Care
22 Dec 2021
Contributed by Lukas
How can we improve psychopharmacology practice? This podcast features a lively discussion among the authors of two articles in the January-February 20...
Risk of Breast Cancer With Prolactin Elevating Antipsychotic Drugs
14 Dec 2021
Contributed by Lukas
A large observational study from researchers at Washington University in St. Louis found an elevated risk of breast cancer in women who take some type...
Are the same medications that are used in the acute treatment of depression the most suitable for preventing relapse?
04 Nov 2021
Contributed by Lukas
In the effort to prevent relapse in patients who have experienced depressive episodes, it has been common practice to have them continue long-term on ...
Lifetime cannabis use disorder is not associated with lifetime impulsive behavior and severe violence in patients with schizophrenia spectrum disorders from a high-security hospital
04 Nov 2021
Contributed by Lukas
The link between substance abuse, impulsivity, and violence in psychotic patients remains unclear. In this author podcast, Gabriella Gobbi, MD, PhD, a...
Esketamine Nasal Spray for the Rapid Reduction of Depressive Symptoms in Major Depressive Disorder With Acute Suicidal Ideation or Behavior
20 Aug 2021
Contributed by Lukas
Individuals with major depressive disorder and suicidal ideation are particularly vulnerable and may not respond as well to standard treatment as pati...
The Placenta and Psychiatry?
20 Aug 2021
Contributed by Lukas
Dr. Julia Ann Koretski reflects on the critical role of the placenta in drug metabolism and potential near- and long-term effects on postanatal life. ...
Time to reconsider monoamine oxidase inhibitors (MAOIs) for Obsessive Compulsive Disorder? A case series using phenelzine
08 Jul 2021
Contributed by Lukas
Obsessive compulsive disorder (OCD) can often be effectively treated with cognitive behavioral therapy or serotonin reuptake inhibitors. About one-thi...
Domestic Mass Shooters: The Association With Unmedicated and Untreated Psychiatric Illness
23 Jun 2021
Contributed by Lukas
Mass shootings have become a common occurrence in the United States and elsewhere. In this podcast, author Ira D. Glick discusses the research he and ...
Why Is There No Food and Drug Administration–Approved Medication for Major Depression With Psychotic Features?
23 Jun 2021
Contributed by Lukas
Psychotic depression is a severely disabling illness and is more common than is generally realized. Unfortunately, there is no FDA-approved medication...
Esketamine: A Drug to Treat Resistant Depression That Brings More Questions Than Answers
10 May 2021
Contributed by Lukas
Authors Nicholas A. Mischel and Richard Balon discuss their commentary, "Esketamine: A Drug to Treat Resistant Depression That Brings More Questions T...
The Pitfalls of Psychotropic Polypharmacy
22 Apr 2021
Contributed by Lukas
Editor-in-Chief Anthony Rothschild discusses his editorial, "The Pitfalls of Psychotropic Polypharmacy." For psychiatric disorders, it is common for p...